IL-6 inhibitors and JAK inhibitors as favourable treatment options for patients with anaemia and rheumatoid arthritis: ANSWER cohort study
Authors' conclusion
IL-6Ri and JAKi can effectively treat patients with anaemia and RA in a real-world setting.
Study context
- Population
- Patients with RA in the multicentre observational ANSWER registry, Japan, classified by tertiles of baseline haemoglobin (Hb) (Hblow, anaemic; Hbint, intermediate; Hbhigh, non-anaemic)
- Participants
- 2,093 patients
- Exposure
- b/tsDMARDs with different modes of action (TNFi, cytotoxic T-lymphocyte antigen (CTLA-4-Ig), IL-6Ri, JAKi) in RA stratified by baseline Hb tertile
- Outcome
- Change in Hb levels, drug retention rates and disease activity after b/tsDMARD administration
Methodological detailsmulticentre, registry-based
- Multicentre
- Registry-based
Main finding
As reported in the abstract
Mean change in Hb (g/dl) by baseline Hb tertile · 12 months
- IL-6Ri, Hblow
- +1.5 g/dl
- IL-6Ri, Hbint
- +0.7 g/dl
- IL-6Ri, Hbhigh
- +0.1 g/dl
- JAKi, Hblow
- +0.6 g/dl
- JAKi, Hbint
- 0 g/dl
- JAKi, Hbhigh
- −0.3 g/dl
Observational data: associations, not effects.
Further findings
Overall adjusted 3-year drug retention rate in patients with anaemia and RA · adjusted
Change of disease activity · 12 months
- Not different among different b/tsDMARD treatments
Original publication
IL-6 inhibitors and JAK inhibitors as favourable treatment options for patients with anaemia and rheumatoid arthritis: ANSWER cohort study. Rheumatology (Oxford). Published 24 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →